Mutation Resistance Could Differentiate Shionogi/ViiV’s Dolutegravir
This article was originally published in The Pink Sheet Daily
Full data from the Phase III SPRING-2 trial released at the International AIDs Conference revealed ViiV/Shionogi’s experimental integrase inhibitor dolutegravir had no resistance mutations compared to Merck’s Isentress.
You may also be interested in...
Gilead Files Once-Daily Integrase Inhibitor Elvitegravir With FDA
Part of the Quad combination product, stand-alone elvitegravir could open up the integrase inhibitor market. In a study supporting the single-agent NDA, once-daily elvitegravir proved comparable to Merck’s twice-daily blockbuster Isentress, the only commercially available integrase inhibitor.
Profile Of Viiv’s Unboosted Dolutegravir Emerges With First Phase III Results
Viiv Healthcare/Shionogi’s once-daily, unboosted integrase inhibitor dolutegravir is efficacious and well-tolerated in the first of four Phase III HIV trials to report, a study of treatment-naïve patients. Drug poses a competitive threat to Merck’s blockbuster Isentress and Gilead’s elvitegravir, part of the four-in-one “Quad” pill.
Forest Files Memantine/Donepezil Fixed Combination For Alzheimer’s
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.